Indeed, we found that CDK4/6 inhibitors reduce mutant p53 expression and subsequently suppress tumor cell proliferation in both RB-proficient and RB-deficient triple-negative breast cancer (TNBC) cells. This evidence concerns the gene TP53 and neoplasm.